drugset
drugset / Trial / NCT04868968

Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)

NCT04868968 ↗

Phase 2 Completed 4 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this phase II study was to assess the safety, tolerability and efficacy of DFV890 in participants with FCAS.

Timeline

Start
2021-09-20
Primary completion
2022-12-13
Completion
2023-05-05

Drugs

EvaluationDrugModalityDoseRoute
Subject DFV890 Unknown 100 mg —

Indications

familial cold autoinflammatory syndrome